News about Global Pharma

Enspire DBS Therapy Raises USD 10.3M Series B1 to Advance Post-Stroke Neuromodulation Trial

The funding led by Genesys Capital will support continued enrollment in Enspire’s pivotal restore clinical trial evaluating deep brain stimulation combined with rehabilitation for stroke recovery.

Global Pharma | 14/01/2026 | By News Bureau |  313

Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies

Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.

Global Pharma | 13/01/2026 | By Darshana |  372

Just-Evotec Biologics Secures Gates Foundation Grant to Expand Global Access to Biotherapeutics

The funding will support ten new molecular design projects over three years, leveraging Just-Evotec Biologics’ J.MD computational platform to optimise monoclonal antibodies and other biologics, reduce development costs and improve access to affordable therapies for infectious diseases in low- and middle-income countries.

Global Pharma | 12/01/2026 | By News Bureau |  169

Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial

Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.

Global Pharma | 09/01/2026 | By News Bureau |  194

PAI Pharma, Olympus Partners Acquire Nivagen to Expand US Sterile Injectable Manufacturing

Deal strengthens domestic pharmaceutical production with advanced aseptic facility and robust ready-to-use injectable pipeline.

Global Pharma | 09/01/2026 | By News Bureau |  382

SPARC Announces Major Workforce Reduction, Shifts to Hybrid R&D Model

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced plans to reduce its workforce by around 40% as part of a broader restructuring aimed at streamlining operations and optimising costs. The impact will be most pronounced in the United States, where more than 80% of employees are expected to be laid off, according to company disclosures.

Global Pharma | 09/01/2026 | By Darshana |  530

GSK Secures EU Approval for Simplified Shingrix Presentation in Prefilled Syringe

GSK plc announced that the European Commission (EC) has approved a new prefilled syringe presentation of Shingrix, the company’s recombinant zoster vaccine (RZV), aimed at simplifying administration for healthcare professionals across the European Union.

Global Pharma | 08/01/2026 | By Darshana |  181

Amgen Acquires UK- based Dark Blue Therapeutics in 840M USD Deal

Amgen’s acquisition of Dark Blue Therapeutics, adds a first-in-class protein degrader programme targeting MLLT1/3-driven acute myeloid leukemia to strengthen its early-stage oncology pipeline.<br />

Global Pharma | 07/01/2026 | By News Bureau |  131

Japan Approves Exdensur for Severe Asthma and Nasal Polyps

Japan has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic in the country, with approval supported by phase-III SWIFT and ANCHOR trial data demonstrating sustained efficacy with twice-yearly dosing.

Global Pharma | 07/01/2026 | By News Bureau |  295

China Approves Nucala from GSK for Adult COPD Treatment

China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.

Global Pharma | 06/01/2026 | By News Bureau |  327